1. Scrip

Merck/Bayer's Vericiguat Could Bring A New Dynamic For Heart Failure

 
• By Jessica Merrill

The Phase III VICTORIA study evaluating the safety of the sGC stimulator met its primary endpoint.

Autumn red leaf with cut heart in a hand - Image
Vericiguat helped certain patients with chronic heart failure in a Phase III study • Source: Shutterstock

Merck & Co. Inc. and Bayer AG appear to have cleared a major hurdle with positive Phase III data in hand on its soluble guanylate cyclase (sGC) stimulator in development to treat patients with chronic heart failure with reduced ejection fraction (HFrEF). Merck announced on 18 November that the Phase III VICTORIA study evaluating the efficacy and safety of vericiguat met its primary endpoint.

The companies only released topline data from the trial, but said vericiguat reduced the risk of the composite endpoint in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Scrip

Multiple Factors Driving Japan’s Pioneering Angiosarcoma Pipeline

 
• By Lisa Takagi

Japan has emerged as a global leader in the development of new drugs for the rare cancer angiosarcoma, reflecting its rapidly ageing population and the limitations of current therapies.

Bristol’s Q2 Earnings Homerun Overshadowed By Clinical Trial Review Curveball

 
• By Mandy Jackson

Second quarter revenue and EPS beat consensus and BMS raised its 2025 revenue guidance, but after multiple recent Phase III failures, executives said the company is reviewing studies with near-term readouts.

AbbVie Raises Full-Year Sales Guidance On Skyrizi/Rinvoq Strength

 
• By Joseph Haas

AbbVie now expects the two Humira successors to bring in $25bn this year. On its Q2 earnings call, the firm also pointed to strength in neuroscience, with 24% growth.